BRTX - שווי פעילות לרווח לפני ריבית, מסים ופחת BioRestorative Therapies, Inc.

BioRestorative Therapies (BRTX) operates a sterile cell cultivation facility in New York, ensuring comprehensive quality control. However, global instability and sanctions are currently complicating biomaterial logistics and international testing. This chart on GURU.Markets shows an EV/EBITDA of 0.00. The company is currently focusing on patenting R&D and advancing its back disease therapy to Phase 2 FDA trials.
BRTX (biorestorative.com): פילוחים אנליטיים ודוחות לפי אינדיקטורים

For the BioRestorative Therapies (BRTX) biotech ecosystem and its capital-intensive ThermoStem platform, this indicator determines the business value relative to earnings before interest, taxes, depreciation, and amortization. An analysis of the current EV/EBITDA multiple allows investors to understand how effectively BioRestorative Therapies (BRTX) capitalizes its patents amidst high costs, accounting for total debt and the market value of assets.